Montiget of Getz Pharma is a selective and orally active leukotrine receptor antagonist. Montiget inhibits the systeinyl leukotrine sysLT1 receptor, stimulation of which by circulating leukotrine in thought to play a role in the pathogenesis of Asthma. Montiget suppresses both early and late bronchoconstrictor resposes to inhale antigens or irritants, but is not suitable for the management of acute attacks of asthma. Montiget is chemically montelukast sodium.
Mechanism of Action
Montiget selectively antagonizes leukotrine D4 (LTD4) at the systeinyl leukotrine receptor, sysLT1, in the human airway. Montiget inhibits the action of LTD4 at the sysLT1 receptor, preventing airway edema smooth muscle contraction and enhance secretion of thick, viscous mucus.
Montiget is indicated in adult and paediatric patients six months of age and older for the prophylaxis in chronic treatment of asthma including;
Montiget is contraindicated in a patient who has shown hypersensitivity to the drug or any of its components. Montiget is not indicated for use in acute asthma attacks including status asthmaticus.
The Montiget should be taken once daily for the management of Asthma.